Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort

Frontiers in Oncology
Pedro BarataMehmet A Bilen

Abstract

Introduction: The treatment landscape of metastatic renal cell carcinoma has advanced significantly with the approval of combination regimens containing an immune checkpoint inhibitor (ICI) for patients with treatment-naïve disease. Little information is available regarding the activity of single-agent ICIs for patients with previously untreated mRCC not enrolled in clinical trials. Methods: This retrospective, multicenter cohort included consecutive treatment-naïve mRCC patients from six institutions in the United States who received ≥1 dose of an ICI outside a clinical trial, between June 2017 and October 2019. Descriptive statistics were used to analyze outcomes including objective best response rate (ORR), progression-free survival (PFS), and tolerability. Results: The final analysis included 27 patients, 70% men, median age 64 years (range 42-92), 67% Caucasian, and 33% with ECOG 2 or 3 at baseline. Most patients had intermediate risk (85%, IMDC) with clear cell (56%), papillary (26%), unclassified (11%), chromophobe (4%), and translocation (4%) RCC. All patients had evidence of metastatic disease involving the lungs (59%), lymph node (41%), CNS (19%), liver (11%), adrenal gland (11%), and bone (11%). The median time on IC...Continue Reading

References

Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel Y C HengToni K Choueiri
Sep 26, 2015·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 025 Investigators
Sep 30, 2017·CA: a Cancer Journal for Clinicians·Pedro C Barata, Brian I Rini
Jan 31, 2018·Journal for Immunotherapy of Cancer·Vadim S KoshkinBrian I Rini
Mar 22, 2018·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 214 Investigators
Feb 20, 2019·The New England Journal of Medicine·Robert J MotzerToni K Choueiri
May 21, 2019·Journal of Immunotherapy·Nalan A Babacan, Tawee Tanvetyanon
Nov 14, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradley A McGregorToni K Choueiri
Jan 9, 2020·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal

❮ Previous
Next ❯

Software Mentioned

OMNIVORE
SPSS Statistics

Related Concepts

Related Feeds

CNS Lymphatics

The CNS contains lymphatic vessels in the meninges that connect and drain the CSF into the peripheral lymphatic system. Impaired functioning of the CNS lymphatic system can be dangerous with the accumulation of toxic substances such as amyloid protein that is part of Alzheimer’s disease pathogenesis. Here is the latest research on the CNS lymphatics.